dc.contributor.author | Cook, G | |
dc.contributor.author | John Ashcroft, A | |
dc.contributor.author | Pratt, G | |
dc.contributor.author | Popat, R | |
dc.contributor.author | Ramasamy, K | |
dc.contributor.author | Kaiser, M | |
dc.contributor.author | Jenner, M | |
dc.contributor.author | Henshaw, S | |
dc.contributor.author | Hall, R | |
dc.contributor.author | Sive, J | |
dc.contributor.author | Stern, S | |
dc.contributor.author | Streetly, M | |
dc.contributor.author | Bygrave, C | |
dc.contributor.author | Soutar, R | |
dc.contributor.author | Rabin, N | |
dc.contributor.author | Jackson, GH | |
dc.contributor.author | United Kingdom Myeloma Forum | |
dc.date.accessioned | 2020-07-06T13:48:38Z | |
dc.date.issued | 2020-07 | |
dc.identifier.citation | British journal of haematology, 2020, 190 (2), pp. e83 - e86 | |
dc.identifier.issn | 0007-1048 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3812 | |
dc.identifier.eissn | 1365-2141 | |
dc.identifier.doi | 10.1111/bjh.16874 | |
dc.format | Print-Electronic | |
dc.format.extent | e83 - e86 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | United Kingdom Myeloma Forum | |
dc.subject | Humans | |
dc.subject | Pneumonia, Viral | |
dc.subject | Coronavirus Infections | |
dc.subject | Multiple Myeloma | |
dc.subject | Recurrence | |
dc.subject | Antineoplastic Agents | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Clinical Audit | |
dc.subject | Pandemics | |
dc.subject | United Kingdom | |
dc.subject | Betacoronavirus | |
dc.subject | COVID-19 | |
dc.subject | SARS-CoV-2 | |
dc.title | Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. | |
dc.type | Other | |
rioxxterms.versionofrecord | 10.1111/bjh.16874 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-07 | |
rioxxterms.type | Other | |
dc.relation.isPartOf | British journal of haematology | |
pubs.issue | 2 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group | |
pubs.publication-status | Published | |
pubs.volume | 190 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Myeloma Group | |
dc.contributor.icrauthor | Kaiser, Martin | |